Table 1.
Baseline characteristics of the patients n (%)
| Variables | |
| Female | 18 (54.4) |
| Mean age | 13 |
| Extent of disease | |
| Proctitis | 0 |
| Left-side colitis | 12 (30) |
| Extensive colitis | 21 (70) |
| Current smokers | 2 (11.1) |
| Endoscopic Mayo score 2-3 | 30 (100) |
| No previous endoscopy | 3 |
| Clinical situation before golimumab | |
| Mild-remission | 5 (15.2) |
| Moderate-severe | 28 (84.8) |
| Golimumab indication | |
| Induction of remission | 28 (84.8) |
| Maintenance of remission | 3 (9.1) |
| Extra-intestinal manifestations | 2 (11.1) |
| Previous anti-TNF use | 24 (72.7) |
| Use of > 1 anti-TNF | 16 (48.5) |
| Previous anti-TNF failure | |
| Primary non-responders | 6 (25) |
| Loss of response | 14 (58.3) |
| Infusion reaction | 4 (16.6) |
| Previous steroid consumption (31 patients had previous steroid consumption) | |
| Steroid-refractory | 7 (27.3) |
| Steroid-dependent | 24 (72.7) |
| Use of steroids at induction | 25 (75.7) |
| Associated immunosuppressors | 12 (36.6) |
| Azathioprine | 11 (33.3) |
| Tacrolimus | 1 (3) |